Viking Therapeutics Completes $547.8M Equity and Debt Financings

What Happened
Viking Therapeutics announced that it completed concurrent equity and debt offerings that together generated approximately $547.8 million in net proceeds. The company entered underwriting agreements on September 23, 2026; both offerings closed on September 25, 2026. The equity offering sold 7,857,143 shares at $35.00 per share and included a full exercise of a 30‑day option for an additional 1,178,571 shares, yielding net proceeds of about $297.0 million. The debt offering sold $225.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2032, with the underwriters’ full exercise of a $33.75 million option, producing net proceeds of about $250.8 million.

Key Details

• Equity offering: 7,857,143 shares at $35.00/share; additional 1,178,571 shares issued on option; net proceeds ≈ $297.0M.
• Debt offering: $225.0M principal 2.00% Convertible Senior Notes due Oct 15, 2032; $33.75M option exercised in full; net proceeds ≈ $250.8M.
• Initial conversion rate: 19.7044 shares per $1,000 principal (≈ $50.75 per share conversion price); conversions settle in cash, stock or combination.
• Notes pay 2.00% interest semi‑annually, are senior unsecured, and include customary conversion, redemption (including make‑whole and cleanup redemptions), and default provisions.

Why It Matters
For investors, this financing meaningfully strengthens Viking’s cash position — roughly $547.8M added — which the company plans to use to advance its VK2735 and VK3019 clinical programs and for general R&D, working capital and corporate purposes. The equity sale diluted existing shareholders at $35.00 per share; the convertible notes introduce potential future dilution if converted (initial conversion price ≈ $50.75/share). The notes are senior unsecured and mature in 2032, carrying a low 2.00% coupon but include features (conversion rights, redemption triggers, make‑whole adjustments) that can affect timing and magnitude of dilution or cash redemption in certain corporate or stock‑price scenarios.